Nevro (NYSE:NVRO) today posted second-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates. The Redwood City, Calif.–based company reported losses of -$21.6 million, or -62¢ per share, on sales of $102.3 million for the three months ended June 30 for a sales growth of 81.47% compared with Q2 2020. Earnings per […]
Nevro Corp.
FDA approves Nevro’s Senza system to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. The Redwood City, Calif.-based company’s stock was up nearly 6%, to 152.54 per share, by afternoon trading today. Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation. The company is touting that it […]
9 medical devices you should keep an eye out for in 2021
The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021. Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek approval or […]
Nevro touts data supporting use of Senza system to treat diabetic neuropathy pain
Nevro (NYSE:NVRO) today touted results from a trial of its Senza system for treating painful diabetic neuropathy (PDN)-related chronic pain. Redwood City, Calif.-based Nevro, which published the results of the SENZA-PDN trial in JAMA Neurology, said in a news release that, if approved, the Senza spinal cord stimulation (SCS) system would be the first FDA-approved […]
The top 7 medtech CEO quotes on COVID-19, one year later
The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world […]
Nevro posts Street-beating Q4 results
Nevro (NYSE:NVRO) posted fourth-quarter results that beat the consensus forecast on Wall Street as it issued 2021 guidance that was slightly below analysts’ expectations. The Redwood City, Calif.–based spinal cord stimulation system maker reported a loss of –$7.2 million, or –21¢ per share, on sales of $109.7 million for the three months ended Dec. 31, 2020, […]
Nevro, Boston Scientific bury the hatchet in one IP case
Boston Scientific (NYSE:BSX) and Nevro (NYSE:NVRO) announced today that they have agreed to end Nevro’s patent infringement lawsuit against the larger company. Nevro had filed suit in the Northern District of California relating to high frequency paresthesia-free spinal cord stimulation (SCS) therapy. The official dismissal of the case is subject to the approval of the court. Boston […]
Nevro names VP, investor relations, corporate communications
Nevro (NYSE:NVRO) today said it appointed Julie Dewey as VP of investor relations and corporate communications, effective immediately. Dewey has more than 25 years of experience in investor relations, corporate communications and marketing in several medical technology companies. She most recently served as senior VP and chief communications officer of Wright Medical, which was recently acquired […]
Nevro rises on Street-beating Q3
Nevro (NYSE:NVRO) shares ticked up today on third-quarter results that came in ahead of the consensus forecast. The Redwood City, Calif.-based chronic pain treatment developer posted losses of -$10 million, or -29¢ per share, on sales of $108.5 million for the three months ended Sept. 30, 2020, for a 44.1% bottom-line gain on sales growth of […]
Nevro appoints Stryker veteran as CFO
Nevro (NYSE:NVRO) announced today that it appointed Roderick MacLeod as its new chief financial officer, effective June 15. MacLeod will succeed current CFO Andrew Galligan, who is set to retire, but will remain on with the company during a transition period as MacLeod takes over. Galligan spent 10 years at Nevro, according to a news release. […]
Nevro Senza Omnia SCS wins CE Mark
Nevro (NYSE:NVRO) announced today that it has received CE mark approval for the Senza Omnia spinal cord stimulation (SCS) system. The system won FDA approval in November 2019. It is is the first and only SCS system designed to deliver Nevro’s proprietary HF10 therapy, as well as other available SCS frequencies, according to the company. Redwood […]